Antengene Corporation Ltd. - B: directors' dealings · Hong Kong · HKEX HKEX:antengene-corporation-ltd-b HK HK · HKEX Mcap 2.8Bn€ Healthcare
Explore the full insider trade history of Antengene Corporation Ltd. - B, a listed issuer based in Hong Kong. Shares are quoted on HK HK, under the authority of HKEX. Operating in the Healthcare sector, Antengene Corporation Ltd. - B has logged 6 public disclosures. Market capitalisation: €2.8bn. The latest transaction was filed on 8 April 2026 — Purchase. Among the most active insiders: Mei Jay. All data is free.
Financial data FY ended December 2025 · cache
Analyst consensus
1 analysts · 5.00 € Target 5.00 €(+8%) 5.00 €
Income statement
Revenue 105.3 M€
Gross profit 88.0 M€ 84% margin
Net income −239.1 M€ -227.0% margin
Balance sheet & cash
Market cap 2.83 Bn€
Total debt 257.5 M€
Free Cash Flow −178.9 M€
Debt / Equity 40%
Profitability & ownership
ROE -32.0%
ROA -11.5%
% insiders 35.8%
% institutions 16.8%
Last declaration on 8 April 2026
Declarations 6 total
Executives ● Purchase3 HKEX
600,000 shares
HKEX:DA20260408E00251 · 2 Apr 2026
Ideal exit: 28 Dec 2026 (T+270) Executives ● Purchase8 HKEX
€106,861 235,000 shares @ €0.4547 0.0038% mcap 48.2% of flow
HKEX:DA20260324E00376 · 24 Mar 2026
Ideal exit: 19 Dec 2026 (T+270) Executives ● Purchase8 HKEX
€5,751 100,000 shares @ €0.0575 0.0002% mcap 51.0% of flow
HKEX:DA20260324E00377 · 24 Mar 2026
Ideal exit: 19 Dec 2026 (T+270) Executives ● Purchase8 HKEX
€114,987 267,500 shares @ €0.4299 0.0041% mcap 51.8% of flow
HKEX:DA20260324E00233 · 23 Mar 2026
Ideal exit: 18 Dec 2026 (T+270) Executives ● Sale3 HKEX
640,000 shares
HKEX:DA20260324E00230 · 23 Aug 2025
Executives ● Purchase8 HKEX
€5,529 100,000 shares @ €0.0553 0.0002% mcap 49.0% of flow
HKEX:DA20260324E00208 · 23 Mar 2026
Ideal exit: 18 Dec 2026 (T+270)